0M2N.L - Orion Oyj

LSE - LSE Delayed price. Currency in EUR

Orion Oyj

Orionintie 1A
Espoo 02200
358 10 4261

Full-time employees3,564

Key executives

NameTitlePayExercisedYear born
Dr. Liisa HurmePres, CEO & Chairman of Exec. Management Board106.13kN/A1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO & Member of the Exec. Management BoardN/AN/A1961
Mr. Olli Huotari Ll.M.Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management BoardN/AN/A1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. BoardN/AN/A1966
Ms. Virve Laitinen M.Sc. (Tech.), MBASr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. BoardN/AN/A1972
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/AN/A1962
Mr. Juhani KankaanpaaSr. VP of Global Operations & Member of Exec. Management BoardN/AN/AN/A
Mr. Niclas Lindstedt EMBA, M.Sc.Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. BoardN/AN/AN/A
Mr. Hao Pan M.Sc.Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. BoardN/AN/A1971
Mr. Tuukka Hirvonen M.Sc.(Soc.)Investor Relations & Financial Communications OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. The company was founded in 1917 and is headquartered in Espoo, Finland.

Corporate governance

Orion Oyj’s ISS governance QualityScore as of 1 May 2023 is 3. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 10; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.